The story of the erectile dysfunction drug presents a intricate picture for those considering investment. While the initial introduction generated massive gains, the end of its patent opened the floodgates to off-brand alternatives, dramatically diminishing market share. This poses a particular challenge for pharmaceutical companies banking on simi

The history of Viagra, and its parent company copyright, presents a complex case study for investors. Originally a blockbuster drug, generating billions in sales , its patent expiration created a wave of knock-off medications, significantly diminishing its dominance. While certain firms may attempt to capitalize on male sexual dysfunction, the exis